Monoclonal antibodies are used to detect serum antigens associated with specific malignancies.
These tumor markers are most useful for monitoring response to therapy and detecting early relapse. With the exception of prostate-specific antigen (PSA), tumor markers do not have sufficient sensitivity or specificity for use in screening.